Efficacy and safety of elobixibat in hemodialysis patients with chronic constipation: a retrospective study
Abstract Background Hemodialysis patients are likely to develop constipation as a complication due to food and fluid restrictions. Elobixibat is a new laxative that inhibits the ileal bile acid transporter expressed in the terminal ileum, suppresses bile acid reabsorption, increases the amount of bi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-04-01
|
| Series: | Renal Replacement Therapy |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s41100-020-00267-y |
| _version_ | 1828155709219405824 |
|---|---|
| author | Takefumi Shono Hiroyuki Hyakutake |
| author_facet | Takefumi Shono Hiroyuki Hyakutake |
| author_sort | Takefumi Shono |
| collection | DOAJ |
| description | Abstract Background Hemodialysis patients are likely to develop constipation as a complication due to food and fluid restrictions. Elobixibat is a new laxative that inhibits the ileal bile acid transporter expressed in the terminal ileum, suppresses bile acid reabsorption, increases the amount of bile acid flowing into the colon lumen, and promotes water secretion in the colon and colon motility. In this study, we examined the efficacy and safety of elobixibat in maintenance hemodialysis patients with chronic constipation. Methods In a study conducted on maintenance hemodialysis patients with chronic constipation, comparisons were conducted retrospectively based on constipation symptoms such as the frequency of spontaneous bowel movements before elobixibat treatment and 12 weeks after the administration of elobixibat, as well as based on blood electrolyte levels. Results The study was conducted on 23 patients, 19 of whom were subjected to treatment efficacy analysis. The frequency of spontaneous bowel movements was 2.0 ± 0.7 times/week before administration of elobixibat and reached 4.9 ± 2.3 times/week after 12 weeks of administration. The increase started after 1 week of treatment. Elobixibat treatment improved the constipation score (baseline, 10.4 ± 3.2; after 12 weeks, 5.7 ± 3.2), the Bristol Stool Form Scale (baseline, 2.2 ± 1.0; after 12 weeks, 4.2 ± 0.7), and patient satisfaction regarding defecation (baseline, 2.9 ± 0.9; after 12 weeks, 1.7 ± 1.1). The interdialytic weight gain (IDWG) was 5.68 ± 0.82% before initiation of treatment and decreased to 4.54 ± 1.34% after 12 weeks. The serum inorganic phosphorus (IP) levels were 5.68 ± 1.25 mg/dL and decreased to 4.93 ± 1.10 mg/dL after 12 weeks. Conclusions Elobixibat was effective in improving constipation symptoms in maintenance hemodialysis patients with chronic constipation. Elobixibat also improved dialysis-related laboratory test results, such as a decrease in serum IP levels and IDWG. Trial registration UMIN Clinical Trials Registry, UMIN000037285 , retrospectively registered |
| first_indexed | 2024-04-11T22:57:43Z |
| format | Article |
| id | doaj.art-dc5992b31d484f58af5a50d4dfbac9ab |
| institution | Directory Open Access Journal |
| issn | 2059-1381 |
| language | English |
| last_indexed | 2024-04-11T22:57:43Z |
| publishDate | 2020-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Renal Replacement Therapy |
| spelling | doaj.art-dc5992b31d484f58af5a50d4dfbac9ab2022-12-22T03:58:19ZengBMCRenal Replacement Therapy2059-13812020-04-01611910.1186/s41100-020-00267-yEfficacy and safety of elobixibat in hemodialysis patients with chronic constipation: a retrospective studyTakefumi Shono0Hiroyuki Hyakutake1Hyakutake ClinicHyakutake ClinicAbstract Background Hemodialysis patients are likely to develop constipation as a complication due to food and fluid restrictions. Elobixibat is a new laxative that inhibits the ileal bile acid transporter expressed in the terminal ileum, suppresses bile acid reabsorption, increases the amount of bile acid flowing into the colon lumen, and promotes water secretion in the colon and colon motility. In this study, we examined the efficacy and safety of elobixibat in maintenance hemodialysis patients with chronic constipation. Methods In a study conducted on maintenance hemodialysis patients with chronic constipation, comparisons were conducted retrospectively based on constipation symptoms such as the frequency of spontaneous bowel movements before elobixibat treatment and 12 weeks after the administration of elobixibat, as well as based on blood electrolyte levels. Results The study was conducted on 23 patients, 19 of whom were subjected to treatment efficacy analysis. The frequency of spontaneous bowel movements was 2.0 ± 0.7 times/week before administration of elobixibat and reached 4.9 ± 2.3 times/week after 12 weeks of administration. The increase started after 1 week of treatment. Elobixibat treatment improved the constipation score (baseline, 10.4 ± 3.2; after 12 weeks, 5.7 ± 3.2), the Bristol Stool Form Scale (baseline, 2.2 ± 1.0; after 12 weeks, 4.2 ± 0.7), and patient satisfaction regarding defecation (baseline, 2.9 ± 0.9; after 12 weeks, 1.7 ± 1.1). The interdialytic weight gain (IDWG) was 5.68 ± 0.82% before initiation of treatment and decreased to 4.54 ± 1.34% after 12 weeks. The serum inorganic phosphorus (IP) levels were 5.68 ± 1.25 mg/dL and decreased to 4.93 ± 1.10 mg/dL after 12 weeks. Conclusions Elobixibat was effective in improving constipation symptoms in maintenance hemodialysis patients with chronic constipation. Elobixibat also improved dialysis-related laboratory test results, such as a decrease in serum IP levels and IDWG. Trial registration UMIN Clinical Trials Registry, UMIN000037285 , retrospectively registeredhttp://link.springer.com/article/10.1186/s41100-020-00267-yElobixibatHemodialysisConstipationSpontaneous bowel movementsSerum phosphorus levelsInterdialytic weight gain |
| spellingShingle | Takefumi Shono Hiroyuki Hyakutake Efficacy and safety of elobixibat in hemodialysis patients with chronic constipation: a retrospective study Renal Replacement Therapy Elobixibat Hemodialysis Constipation Spontaneous bowel movements Serum phosphorus levels Interdialytic weight gain |
| title | Efficacy and safety of elobixibat in hemodialysis patients with chronic constipation: a retrospective study |
| title_full | Efficacy and safety of elobixibat in hemodialysis patients with chronic constipation: a retrospective study |
| title_fullStr | Efficacy and safety of elobixibat in hemodialysis patients with chronic constipation: a retrospective study |
| title_full_unstemmed | Efficacy and safety of elobixibat in hemodialysis patients with chronic constipation: a retrospective study |
| title_short | Efficacy and safety of elobixibat in hemodialysis patients with chronic constipation: a retrospective study |
| title_sort | efficacy and safety of elobixibat in hemodialysis patients with chronic constipation a retrospective study |
| topic | Elobixibat Hemodialysis Constipation Spontaneous bowel movements Serum phosphorus levels Interdialytic weight gain |
| url | http://link.springer.com/article/10.1186/s41100-020-00267-y |
| work_keys_str_mv | AT takefumishono efficacyandsafetyofelobixibatinhemodialysispatientswithchronicconstipationaretrospectivestudy AT hiroyukihyakutake efficacyandsafetyofelobixibatinhemodialysispatientswithchronicconstipationaretrospectivestudy |